1. Home
  2. RZLT vs ACIU Comparison

RZLT vs ACIU Comparison

Compare RZLT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$2.35

Market Cap

187.3M

Sector

Health Care

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$3.44

Market Cap

213.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RZLT
ACIU
Founded
2010
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.3M
213.3M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
RZLT
ACIU
Price
$2.35
$3.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
$10.33
$10.00
AVG Volume (30 Days)
15.9M
1.6M
Earning Date
02-11-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,482,957.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$644.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$1.43
52 Week High
$11.46
$4.00

Technical Indicators

Market Signals
Indicator
RZLT
ACIU
Relative Strength Index (RSI) 34.56 57.20
Support Level $1.87 $3.09
Resistance Level $2.43 $3.73
Average True Range (ATR) 0.29 0.20
MACD 0.21 0.05
Stochastic Oscillator 56.73 67.44

Price Performance

Historical Comparison
RZLT
ACIU

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: